Dan Takefman is the Chief Development Officer at Rhygaze. Dr Takefman joined the

company in March of 2025. Prior to joining Rhygaze, Dr. Takefman was SVP and Head of Regulatory Affairs at Spark Therapeutics for 5 years. At Spark, Dr. Takefman supervised the submission through to approval of the FDA and EMA Luxturna® marketing applications. Dan also supervised the regulatory process for multiple AAV based investigation products including two additional Breakthrough Designation products: SPK-9001 for the treatment of Hemophilia B (marketing applications currently under review by FDA and EMA) and SPK-8011 for the treatment of Hemophilia A. Dr. Takefman joined the FDA Division of Cellular and Gene Therapy in 1999 as a Postdoctoral Fellow. Dan held multiple positions during his 15-year career at FDA, ultimately becoming Chief of the Gene Therapy Branch. He supervised the Chemistry, Manufacturing and Control (CMC) review process for all gene therapy products and for a variety of therapeutic vaccine products. Dr. Takefman holds a Ph.D. in Immunology from Rush University and a B.S. in Microbiology from the University of Iowa.